



AREN-0239 (11.US9.DIV)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Chen W. Liaw et al.

Confirmation No.: 6379

Serial No.: 09/875,076

Art Unit: 1646

Filing Date: June 6, 2001

Examiner: Prema Maria Mertz

For: HUMAN ORPHAN G PROTEIN-COUPLED RECEPTORS

Customer No.: 35133

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

VIA EXPRESS MAIL LABEL NO: EV146 601 123US

DATE SENT: September 19, 2005

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449, submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
- ☐ before the mailing date of a first Office Action on the merits.
- ☒ after the mailing date of a first Office Action on the merits, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:

☐ the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);

or

☒ the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or

09/22/2005 MAHMED1 00000046 501275 09875076

01 FC:1806

180.00 DA

- ☐ No fee is owed by the applicant(s).
- ☐ In accordance with 37 C.F.R. § 1.129(a), this Information Disclosure Statement is being filed in connection with the ☐ first or ☐ second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.
- ☐ **after** the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before, or simultaneously with, the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), a Petition requesting consideration of the Information Disclosure Statement and the Petition Fee of \$130.00 set forth in 37 C.F.R. § 1.17(i)(1) (see "Statement," "Petition," and "Fees" below).
- ☒ Copies of references (HT; IA-IK) listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449, are enclosed.

EXCEPT THAT:

- ☒ Only the first four pages of reference HS, including the first page of the application, are enclosed, in view of the fact that this patent is the Canadian equivalent of WO 00/50562, a copy of which was previously considered by the examiner in the Office Action dated 3 September 2004 (reference BF) and in view of the fact that this patent is readily available to the examiner. However, Applicant will endeavor to supply a copy at the Examiner's request.
- ☐ In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) @@@ for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.
- ☐ Copies of references listed on the attached PTO Form SB/08A, formerly known as PTO Form 1449, were previously cited by or submitted to the U.S. Patent and Trademark Office in parent application Serial No.***, with the exception of AV, which is attached hereto.
- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Statement under 37 C.F.R. § 1.97(e)

- ☐ The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a

foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.

Statement under 37 C.F.R. § 1.704(d)

- ☐ The undersigned attorney hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and the communication was not received by any individual designated in §1.56(c) more than 30 days prior to the filing of the Information Disclosure Statement.

Fees

- ☐ No Fee is owed by the applicant(s).
- ☒ The Information Disclosure Statement Fee of **\$180.00** under 37 C.F.R. § 1.17(p) is enclosed herewith.
- ☐ The Petition Fee of \$130.00 under 37 C.F.R. § 1.17(i)(1) is enclosed herewith.

Method of Payment of Fees

- ☐ Attached is a check in the amount of \$_____. This form is submitted in duplicate.
- ☒ Charge Deposit Account No. 50-1275 in the amount of **\$180.00**. This form is submitted in duplicate.
- ☒ Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.
- ☐ No fee or Statement is required under 37 C.F.R. § 1.97(b).

Respectfully submitted,



Michael A. Patané
Registration No. 42,982

Dated: Sept. 19, 2005

COZEN O'CONNOR, P.C.
1900 Market Street, 5th Floor
Philadelphia, PA 19103-3508
(215) 665-6966- Telephone
(215) 701-2080 - Facsimile

PTO/SB/08A (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to respond to a collection of information unless it contains a valid OMB control number.



If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08B(07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	09/875,076
Filing Date	6 June 2001
First Named Inventor	Chen W. Liaw, et al.
Art Unit	1646
Examiner Name	MERTZ, Prema Maria
Attorney Docket Number	AREN-0239 (11.US9.DIV)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	IA	BLASZCZYK, J., "Motor Deficiency in Parkinson's Disease," <i>Acta Neurobiol. Exp.</i> (1998) 58:79-93.	
	IB	BROUN, P., et al., "Catalytic Plasticity of Fatty Acid Modification Enzymes Underlying Chemical Diversity of Plant Lipids," <i>Science</i> (1998) 282: 1315-1317.	
	IC	FEHMANN, H., "Cell and Molecular Biology of the Incretin Hormones Glucagon-Like Peptide-I and Glucose-Dependent Insulin Releasing Polypeptide," <i>Endocrine Reviews</i> (1995) 16(3):390-410.	
	ID	LEURS, R., et al., "Agonist-independent Regulation of Constitutively Active G-protein-coupled Receptors," <i>TIBS</i> (1998) 23:418-422.	
	IE	MURDOCH, C., et al., "Chemokine Receptors and Their Role in Inflammation and Infectious Diseases," <i>Blood</i> (2000) 95:3032-3043.	
	IF	NG, D., et al., "Point Mutation in the Second Phosphatase Domain of CD45 Abrogates Tyrosine Phosphatase Activity," <i>Biochemical and Biophysical Research Communications</i> (1995) 206 (1): 302-309.	
	IG	PAUWELS, P., et al., "Review: Amino Acid Domains Involved in Constitutive Activation of G-Protein-Coupled Receptors," <i>Molecular Neurobiology</i> (1998) 17:109-135.	
	IH	PROBST, W., et al., "Sequence Alignment of the G-Protein Coupled Receptor Superfamily," <i>DNA and Cell Biology</i> (1992) 11(1):1-20.	
	II	SONNHAMMER, E., "A Hidden Markov Model for Predicting Transmembrane Helices in Protein Sequences," in J. Glasgow, et al., eds., <i>Proc. Sixth Int. Conf. on Intelligent Systems for Molecular Biology</i> , pp. 175-182 (AAAI Press, 1998).	
	IJ	THORENS, B., "Expression Cloning of the Pancreatic β Cell Receptor for the Gluco-incretin Hormone Glucagon-like Peptide 1," <i>Proc. Natl. Acad. Sci. Cell Biology</i> (1992) 89:8641-8645.	
	IK	WATSON, S., <i>The G-Protein Linked Receptor FactsBook</i> , pp. 2; 223-230, (Academic Press, 1994).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.